A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find the highest tolerable dose of AGS67E that can be given either 1 time (or dose) weekly for 3 out of every 4 weeks or every 3 weeks to patients with acute myeloid leukemia (AML). The every 3 week dosing schedule is now closed. The safety of AGS67E, including any effects (good and/or bad) it has on the disease, will also be studied. This consent form is only for participants receiving AGS67E 1 time each week for 3 out of every 4 weeks (Dosing Schedule B).
Treatment Location: N/A
IRB Review and Approval Date: 07/14/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: